GRI Bio, Inc. (GRI) News
Follow GRI Bio, Inc. (GRI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
Chief Executive Officer Marc Hertz and Chief Scientific Officer Vipin Kumar to present on translating immune biology and clinical signals into novel therapeutic approaches for IPFLA JOLLA, CA, Sept. 28, 2026 (GLOBE NEWSW
NEWS | Sep 28, 2026, 12:42 PM UTC
L
HC Wainwright maintains $10.00 price target on GRI Bio
HC Wainwright & Co. maintained a $10.00 per-share price target for GRI Bio, as reported in ratings actions from Benzinga (via TradingView News).
EQUITY | Sep 10, 2026, 05:35 PM UTC
M
GRI Bio reports Phase 2a IPF biomarker and safety data
GRI Bio said Phase 2a translational biomarker and safety data for GRI-0621 showed a placebo-adjusted Week 12 FVC gain overall and on background antifibrotic therapy.
REGULATION | Sep 08, 2026, 12:23 PM UTC
L
GRI - GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars - Click
GRI - GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
EQUITY | Sep 08, 2026, 12:15 PM UTC
L
Grainger targets 35% earnings growth from FY25 to FY29
Grainger PLC says it is on track to grow earnings by 35% from FY25 to FY29.
EARNINGS | Sep 07, 2026, 06:59 AM UTC
L
Grainger targets 35% earnings growth FY25–FY29
The firm cites strong rental demand and high occupancy. It says it has a clear plan to deliver 35% earnings growth from FY25 to FY29, supported by cost reductions, asset disposals and a development pipeline.
EARNINGS | Sep 07, 2026, 06:27 AM UTC
L
GRI - GRI Bio Featured in "Why Now" On-Demand Video Webcast
GRI - GRI Bio Featured in "Why Now" On-Demand Video Webcast
EQUITY | Aug 27, 2026, 01:08 PM UTC
L
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
EQUITY | Aug 27, 2026, 01:01 PM UTC
M
GRI Bio to present Phase 2a GRI-0621 data at ERS 2026
GRI Bio says it will present late-breaking Phase 2a GRI-0621 data on lung function, anti-fibrotic biomarkers and tolerability in IPF at ERS 2026.
EQUITY | Aug 24, 2026, 01:05 PM UTC